These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12377353)

  • 1. In regard to Padula et al., normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer. IJROBP 2002;52: 439-443.
    Dearnaley DP; Norman AR; Shahidi M
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):981; author reply 981. PubMed ID: 12377353
    [No Abstract]   [Full Text] [Related]  

  • 2. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
    Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
    J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localized prostate cancer.
    Shahidi M; Norman AR; Gadd J; Huddart RA; Horwich A; Dearnaley DP
    Clin Oncol (R Coll Radiol); 2001; 13(4):291-5. PubMed ID: 11554629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
    Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer.
    Padula GD; Zelefsky MJ; Venkatraman ES; Fuks Z; Lee HJ; Natale L; Leibel SA
    Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):439-43. PubMed ID: 11872290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide.
    Shim M; Bang WJ; Oh CY; Lee YS; Cho JS
    Investig Clin Urol; 2019 Jul; 60(4):244-250. PubMed ID: 31294133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gonadotropin releasing hormone analogue antiandrogen failure secondary to a pituitary adenoma.
    Ogan K; Berger M; Ball R
    J Urol; 1998 Aug; 160(2):497-8. PubMed ID: 9679910
    [No Abstract]   [Full Text] [Related]  

  • 9. Hormonal therapy of prostate cancer.
    Debruyne F
    Semin Urol Oncol; 2002 Aug; 20(3 Suppl 1):4-9. PubMed ID: 12198632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer.
    Gulley JL; Aragon-Ching JB; Steinberg SM; Hussain MH; Sartor O; Higano CS; Petrylak DP; Chatta GS; Arlen PM; Figg WD; Dahut WL
    J Urol; 2008 Oct; 180(4):1432-7; discussion 1437. PubMed ID: 18710748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy.
    Pickles T
    J Urol; 2005 Dec; 174(6):2423-4; author reply 2424. PubMed ID: 16280866
    [No Abstract]   [Full Text] [Related]  

  • 12. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
    Prescrire Int; 2007 Dec; 16(92):243. PubMed ID: 18092407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal treatment of prostate cancer.
    Garnick MB
    N Engl J Med; 1999 Mar; 340(10):812-3. PubMed ID: 10075531
    [No Abstract]   [Full Text] [Related]  

  • 14. Neoadjuvant androgen withdrawal prior to external radiotherapy for locally advanced adenocarcinoma of the prostate.
    Hara I; Miyake H; Yamada Y; Takechi Y; Hara S; Gotoh A; Fujisawa M; Okada H; Arakawa S; Soejima T; Sugimura K; Kamidono S
    Int J Urol; 2002 Jun; 9(6):322-8; discussion 328. PubMed ID: 12269247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Endocrine therapy for prostate cancer in the future].
    Usami M
    Gan To Kagaku Ryoho; 1998 May; 25(6):817-22. PubMed ID: 9617319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hormonal status in patients with advanced prostatic cancer on the therapy with androgen blockade].
    Vojinov S; Levakov I; Jeremić D; Zivojinov S; Marusić G
    Vojnosanit Pregl; 2011 Apr; 68(4):321-6. PubMed ID: 21630520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy.
    Gulley JL; Figg WD; Steinberg SM; Carter J; Sartor O; Higano CS; Petrylak DP; Chatta G; Hussain MH; Dahut WL
    J Urol; 2005 May; 173(5):1567-71. PubMed ID: 15821487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Total androgen blockade].
    Namiki M; Mizokami A
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():193-8. PubMed ID: 12599570
    [No Abstract]   [Full Text] [Related]  

  • 19. Medicare reimbursement and prescribing hormone therapy for prostate cancer.
    Keating NL
    J Natl Cancer Inst; 2010 Dec; 102(24):1814-5. PubMed ID: 21131579
    [No Abstract]   [Full Text] [Related]  

  • 20. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.